[HTML][HTML] Safety and efficacy of denosumab in children with osteogenesis imperfecta-a first prospective trial
H Hoyer-Kuhn, J Franklin, G Allo, M Kron… - … of musculoskeletal & …, 2016 - ncbi.nlm.nih.gov
Objectives: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial
H Hoyer-Kuhn, J Franklin, G Allo… - Journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Objectives Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
[PDF][PDF] Safety and efficacy of denosumab in children with osteogenesis imperfecta-a first prospective trial
H Hoyer-Kuhn, J Franklin, G Allo, M Kron… - J Musculoskelet …, 2016 - Citeseer
Objectives: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
Safety and efficacy of denosumab in children with osteogenesis imperfecta-a first prospective trial
H Hoyer-Kuhn, J Franklin, G Allo… - J. Musculoskelet …, 2016 - kups.ub.uni-koeln.de
Objectives: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.
H Hoyer-Kuhn, J Franklin, G Allo, M Kron… - … of Musculoskeletal & …, 2016 - europepmc.org
Objectives Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
[PDF][PDF] Safety and efficacy of denosumab in children with osteogenesis imperfecta-a first prospective trial
H Hoyer-Kuhn, J Franklin, G Allo, M Kron… - J Musculoskelet …, 2016 - ismni.org
Objectives: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
[PDF][PDF] Safety and efficacy of denosumab in children with osteogenesis imperfecta-a first prospective trial
H Hoyer-Kuhn, J Franklin, G Allo… - J Musculoskelet …, 2016 - pdfs.semanticscholar.org
Objectives: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
Safety and efficacy of denosumab in children with osteogenesis imperfecta-a first prospective trial
H Hoyer-Kuhn, J Franklin, G Allo… - J. Musculoskelet …, 2016 - kups.ub.uni-koeln.de
Objectives: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.
H Hoyer-Kuhn, J Franklin, G Allo, M Kron… - … of Musculoskeletal & …, 2016 - europepmc.org
Objectives Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …